Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Getting a diagnosis

Topic: Amyloid, tau and blood-test diagnosis

Until recently, accurate early detection of clinical symptoms associated with Alzheimer's disease (AD) and related dementias (ADRD) has been difficult. Digital technologies have created new opportunities to capture cognitive and other AD/ADRD related behaviors with greater sensitivity and specificity. Speech captured through digital recordings has shown recent promise at feasible levels of scalability because of the widespread penetration of smartphones. One such study is described in detail to illustrate the depth in which artificial intelligence (AI) analytic approaches can be used to amplify the value of audio recordings. Another modality that has also attracted research interest are ocular scans that have near term potential for validation as a digital biomarker and a point of entry for clinical care workflows. Single modality measures, however, are rapidly giving way to multi-modality sensors that are embedded in all smartphones and other internet-of-things connected devices. Artificial intelligence (AI) driven analytic approaches are able to divine clinical signals from these high dimensional digital data streams. These data driven findings are setting the stage for a future state in which AD/ADRD detection will be possible at the earliest possible stage of the neurodegenerative process and enable interventions that would significantly attenuate or alter the trajectory, preventing disease from reaching the clinical diagnosis threshold.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Wang, L., Glass, J., Kourtis, L. C., & Au, R. (2025). Multi-modal data analysis for early detection of alzheimer’s disease and related dementias. The Journal of Prevention of Alzheimer s Disease. https://doi.org/10.1016/j.tjpad.2025.100399

Vancouver

Wang L, Glass J, Kourtis LC, Au R. Multi-modal data analysis for early detection of alzheimer’s disease and related dementias. The Journal of Prevention of Alzheimer s Disease. 2025. doi:10.1016/j.tjpad.2025.100399. PMID: 41326294.

BibTeX

@article{wang2025-41326294,
  author  = {Wang, Liming and Glass, Jim and Kourtis, Lampros C. and Au, Rhoda},
  title   = {{Multi-modal data analysis for early detection of alzheimer’s disease and related dementias}},
  journal = {The Journal of Prevention of Alzheimer s Disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2025.100399},
  pmid    = {41326294},
  url     = {https://doi.org/10.1016/j.tjpad.2025.100399}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review describes how digital technologies such as speech recordings, ocular scans, and multi-modality sensors with artificial intelligence could enable earlier detection of Alzheimer's disease and related dementias. It discusses a future state of detection and intervention but does not itself test any treatment, cure or prevention.

Study details

How this study scored 40/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 3 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 40 of 100.40 of 100 points earned60 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The Journal of Prevention of Alzheimer s Disease)
Journal's citation record 0 / 4 The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 5 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.7 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 3.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Rhoda Au: h-index 90 (OpenAlex, whole career)
Institution's track record 3 / 3 Massachusetts Institute of Technology: institution h-index 2,557 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41326294)
Free to read 2 / 2 Free to read
Total 40 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Getting a diagnosis

Also tagged “classification”

835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →